Literature DB >> 33305708

State-of-the-Art Review of Current Therapies for HFpEF: An Overview of Interatrial Septal Device Therapy in Heart Failure.

Mohammed Al-Sadawi1, Romy R Ortega2, Jonathan Ariyaratnam2, Ayman Battisha3, Bader Madoukh4, Inna Bukharovich5.   

Abstract

Heart failure (HF) affects an increasing number of geriatric patients. The condition is classified according to whether the left ventricular ejection fraction (EF) is reduced or preserved. Many patients have heart failure with preserved ejection fraction (HFpEF) and face a shortage of effective therapeutic strategies. However, an emerging mechanical strategy for treatment is gaining momentum. Interatrial septal connection devices, i.e. V-wave device and Interatrial septal device, are new devices for patients with heart failure with preserved ejection fraction. We review the function of these systems and the data from the recent clinical trials. Interatrial septal connection device therapy provided favorable efficacy and safety profile applicable to a wide range of patients with HFpEF. However, the long-term effects of these devices on morbidity. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  IASD; Interatrial device; V-wave; device treatment forzzm321990heart failure.; heart failure; heart failure with preserved ejection fraction

Mesh:

Year:  2021        PMID: 33305708      PMCID: PMC8950450          DOI: 10.2174/1573403X16999201210195455

Source DB:  PubMed          Journal:  Curr Cardiol Rev        ISSN: 1573-403X


  53 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

2.  Spironolactone for heart failure with preserved ejection fraction.

Authors:  Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

3.  Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.

Authors:  Hidekatsu Fukuta; Toshihiko Goto; Kazuaki Wakami; Nobuyuki Ohte
Journal:  Eur J Prev Cardiol       Date:  2014-12-17       Impact factor: 7.804

4.  Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.

Authors:  Ali Ahmed; Michael W Rich; Jerome L Fleg; Michael R Zile; James B Young; Dalane W Kitzman; Thomas E Love; Wilbert S Aronow; Kirkwood F Adams; Mihai Gheorghiade
Journal:  Circulation       Date:  2006-07-24       Impact factor: 29.690

5.  The restoration of chronotropic competence in heart failure patients with normal ejection fraction (RESET) study: rationale and design.

Authors:  David A Kass; Dalane W Kitzman; Guy E Alvarez
Journal:  J Card Fail       Date:  2009-10-07       Impact factor: 5.712

6.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.

Authors:  Gregg C Fonarow; Wendy Gattis Stough; William T Abraham; Nancy M Albert; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Jie Lena Sun; Clyde W Yancy; James B Young
Journal:  J Am Coll Cardiol       Date:  2007-08-06       Impact factor: 24.094

Review 7.  Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis.

Authors:  Nicolas M Berbenetz; Marko Mrkobrada
Journal:  BMC Cardiovasc Disord       Date:  2016-12-01       Impact factor: 2.298

8.  Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction.

Authors:  David M Kaye; Mark C Petrie; Scott McKenzie; Gerd Hasenfuβ; Filip Malek; Martijn Post; Robert N Doughty; Jean-Noël Trochu; Finn Gustafsson; Irene Lang; Adam Kolodziej; Ralf Westenfeld; Martin Penicka; Mark Rosenberg; Jörg Hausleiter; Philip Raake; Guillaume Jondeau; Martin W Bergmann; Tim Spelman; Huseyin Aytug; Piotr Ponikowski; Chris Hayward
Journal:  ESC Heart Fail       Date:  2018-10-11

9.  Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.

Authors:  Daniel N Silverman; Timothy B Plante; Margaret Infeld; Peter W Callas; Stephen P Juraschek; Geoff B Dougherty; Markus Meyer
Journal:  JAMA Netw Open       Date:  2019-12-02

10.  Heart failure with preserved ejection fraction (HFpEF) pathophysiology study (IDENTIFY-HF): does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of comorbidities? Rationale and design.

Authors:  Danish Ali; Nualla Callan; Stuart Ennis; Richard Powell; Scott McGuire; Gordon McGregor; Martin O Weickert; Michelle A Miller; Francesco P Cappuccio; Prithwish Banerjee
Journal:  BMJ Open       Date:  2019-11-19       Impact factor: 2.692

View more
  1 in total

Review 1.  Kaposi sarcoma in anti-neutrophil cytoplasmic antibody-associated vasculitis: a case-based review.

Authors:  Benedict K Tiong; Arun S Singh; G Peter Sarantopoulos; Tanaz A Kermani
Journal:  Rheumatol Int       Date:  2021-02-23       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.